Investigational drug · Phase 3
Clazakizumab
Also called: LY5724886, CSL300
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atherosclerosis, Cardiovascular Disease, Obesity.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
21
Any phase or sponsor naming "Clazakizumab"
First trial start
2024
Apr 27, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Clazakizumab", any sponsor or status.
- Phase 219
Conditions studied
As listed on its trial records.
- Atherosclerosis
- Cardiovascular Disease
- Obesity
- Hypertension
- Diabetes Mellitus, Type 2
- Renal Insufficiency, Chronic
- End Stage Kidney Disease
Approved drugs for the same conditions: Obesity and weight management · High blood pressure (hypertension) · Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Clazakizumab" as an intervention, largest first.
- Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)Pivotal-lookingRecruiting
CSL BehringIndustry
NCT05485961 · 3,110 participants (planned) · Start Apr 27, 2024 · Primary completion May 22, 2029
Drug: CSL300; Placebo · For: End Stage Kidney Disease
Sites: Decatur, Alabama; Huntsville, Alabama; Montgomery, Alabama · 566 sites in all
- PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network StudyPivotal-lookingCompleted
University of North Carolina, Chapel HillAcademic, hospital or other
NCT04129931 · 950 participants · Start Dec 19, 2019 · Primary completion Feb 19, 2025
Drug: MCT; Clazakizumab and 3 more · For: Asthma
Sites: Scottsdale, Arizona; Tucson, Arizona; Sacramento, California · 29 sites in all
- Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to MethotrexatePivotal-lookingCompleted
CSL BehringIndustry
NCT01373151 · 418 participants · Start Jun 2011 · Primary completion Sep 2012
Drug: BMS-945429 Placebo; BMS-945429 and 9 more · For: Rheumatoid Arthritis
Sites: Peoria, Arizona; San Diego, California; Trumbull, Connecticut · 100 sites in all
- Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant RecipientsPivotal-lookingTerminated
CSL BehringIndustry
NCT03744910 · 194 participants · Start Oct 14, 2019 · Primary completion Apr 8, 2024
Drug: Clazakizumab; Physiologic saline solution · For: Antibody-mediated Rejection
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 142 sites in all
- A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 InfectionPivotal-lookingCompleted
NYU Langone HealthAcademic, hospital or other
NCT04343989 · 178 participants · Start Mar 31, 2020 · Primary completion Feb 3, 2021
Drug: Clazakizumab 25 mg; Clazakizumab 12.5 mg · For: COVID-19
Sites: Phoenix, Arizona; Baltimore, Maryland; New York, New York
- Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) TherapyPivotal-lookingCompleted
CSL BehringIndustry
NCT01490450 · 165 participants · Start Dec 2011 · Primary completion Jun 2013
Drug: Placebo matching BMS-945429; BMS-945429 and 2 more · For: Arthritis, Psoriatic
Sites: San Diego, California; Denver, Colorado; Trumbull, Connecticut · 49 sites in all
- Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid ArthritisPivotal-lookingCompleted
CSL BehringIndustry
NCT02015520 · 143 participants · Start Jun 2012 · Primary completion Jun 2013
Drug: Clazakizumab; Placebo (Matching with Clazakizumab) · For: Rheumatoid Arthritis
Sites: Huntsville, Alabama; Hot Springs, Arkansas; Long Beach, California · 55 sites in all
- Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid ArthritisPivotal-lookingCompleted
CSL BehringIndustry
NCT00867516 · 127 participants · Start Oct 2008 · Primary completion Jun 2009
Drug: ALD518; Infusion without ALD518' · For: Arthritis, Rheumatoid
Sites: Kitchener, Canada; Ottawa, Canada; Tbilisi, Georgia · 26 sites in all
- Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and CachexiaPivotal-lookingCompleted
CSL BehringIndustry
NCT00866970 · 124 participants · Start Sep 2008 · Primary completion Aug 2009
Drug: ALD518; ALD518 and 2 more · For: NSCLC; Fatigue; Cachexia
Sites: Auchenflower, Australia; Kippa-Ring, Australia; Adelaide, Australia · 43 sites in all
- A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular EventPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07783802 · 120 participants (planned) · Start Aug 27, 2026 · Primary completion May 2027
Drug: Clazakizumab; Placebo · For: Atherosclerosis; Cardiovascular Disease; Obesity and 3 more
Sites: Huntsville, Alabama; Tucson, Arizona; Glendora, California · 46 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- IL-6 Blockade for Antibody-Mediated Transplant Rejection: What Does the Evidence Say?
Kanbay M, Copur S, Altunbulakli C, et al. · BioDrugs 2026
- IL-6 Blockade with Clazakizumab is Associated with Low Myeloid Cell Activation and Increased Type 2 Immune Responses in Non-survivors of COVID-19.
Stoddart L, Johnston TS, Zhou W, et al. · J Infect Dis 2026
- Reply to comment on "Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study".
Djamali A, Nickerson PW · Am J Transplant 2026
- Comment on "Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study".
Reuter S, Lachmann N, Arnol M · Am J Transplant 2026
- Targeting Inflammation in Chronic Kidney Disease: Pathophysiological Insights and Emerging Therapeutic Strategies.
Tsalouchos A, Dattolo PC · J Clin Med 2026
- Treatment of antibody-mediated rejection in heart transplantation: from empirical combination to multi-target precision intervention.
Xu N, Dong Y, Yue Y, et al. · Front Immunol 2026
Also in development for Atherosclerosis
- LepodisiranLY3819469Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
- YN001Phase 22 trials
Beijing Inno Medicine Co., Ltd. · Atherosclerosis, Coronary Artery Disease, Atherosclerotic Cardiovascular Disease
- VERVE-102LY4636581Phase 21 trial
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.